KFAS
BIO icon

Keating Financial Advisory Services’s Bio-Rad Laboratories Class A BIO Stock Holding History

Keating Financial Advisory Services’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.94K Buy
10
+1
+11% +$284 ﹤0.01% 1792
2026
Q1 		$2.51K Sell
9
-1
-10% -$288 ﹤0.01% 1756
2025
Q4 		$3.03K Buy
+10
New +$3.12K ﹤0.01% 1454

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Keating Financial Advisory Services's BIO Position: Q2 2026 in Review

Keating Financial Advisory Services increased its Bio-Rad Laboratories Class A (BIO) stake by 11% in Q2 2026, buying an estimated $284 and bringing the position to 10 shares worth $2.94K. The position accounts for ﹤0.01% of the portfolio, ranked #1792.

Keating Financial Advisory Services first reported a position in BIO in Q4 2025 and has held it in 3 quarters since. The position peaked at $3.03K in Q4 2025. 400 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Keating Financial Advisory Services held 10 shares of Bio-Rad Laboratories Class A worth $2.94K as of Q2 2026.
  • Keating Financial Advisory Services bought 1 Bio-Rad Laboratories Class A share in Q2 2026, an estimated $284.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Keating Financial Advisory Services's portfolio in Q2 2026, its #1792 holding.
  • Keating Financial Advisory Services first reported a position in Bio-Rad Laboratories Class A in Q4 2025 and has held it in 3 quarters since.
  • Keating Financial Advisory Services's Bio-Rad Laboratories Class A position peaked at $3.03K in Q4 2025.
  • 400 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Keating Financial Advisory Services's 13F filing for Q2 2026, filed 11 Aug 2026.